-
公开(公告)号：US09579398B2
公开(公告)日：2017-02-28
申请号：US14378505
申请日：2013-02-15
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young Seong , Jong Ik Hwang , Woong Sun , Eun Bee Cho , Won-ki Kim
IPC: A61K39/395 , A61P25/00 , A61K48/00 , A61K38/17 , C07K16/18 , C12N15/113 , C07K14/47 , C07K16/24 , C12Q1/68 , A61K39/00
CPC classification number: C07K16/24 , A61K38/1709 , A61K48/00 , A61K2039/505 , C07K14/4701 , C07K14/4702 , C07K16/18 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N15/113 , C12N2310/11 , C12N2310/141 , C12Q1/6886 , C12Q2600/156 , G01N33/577 , G01N33/6896 , G01N2333/47
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
Abstract translation: 本发明涉及涉及调节胶质发生的FAM19A5的药物用途，更具体地说，涉及使用FAM19A5预防，诊断或治疗中枢神经系统损伤，退行性脑病或中枢神经系统疾病，FAM19A5为 在脊椎动物的神经干细胞中扩散并调节胶质细胞发生。
-
公开(公告)号：US12215338B2
公开(公告)日：2025-02-04
申请号：US17053733
申请日：2019-05-08
Applicant: Neuracle Science Co., Ltd. , Neuracle Genetics
Inventor： Jong-Mook Kim , Dong Sik Kim , Juwon Shim , Soon-gu Kwon
Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.
-
公开(公告)号：US12202889B2
公开(公告)日：2025-01-21
申请号：US17723149
申请日：2022-04-18
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol Kim , Jae Young Seong , Jong Ik Hwang , Eun Bee Cho , Junho Chung , Junyeong Jin , Tae Young Yune , Jee Youn Lee
IPC: C07K16/18 , A61K39/00 , C07K7/00 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US11970532B2
公开(公告)日：2024-04-30
申请号：US17054469
申请日：2019-05-10
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Wonkyum Kim , Jeongwon Yoon , Junho Chung , Junyeong Jin , Eunhwoi You
IPC: C07K16/24 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/68 , A61P25/00 , A61P25/02 , A61P29/00 , A61P35/00
CPC classification number: C07K16/24 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61P25/00 , A61P25/02 , A61P29/00 , A61P35/00 , A61K2039/505 , C07K2317/33 , C07K2317/41 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US20230287096A1
公开(公告)日：2023-09-14
申请号：US18177334
申请日：2023-03-02
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol KIM , Jae-Keun LEE , Dong Sik KIM , Junho CHUNG , Junyeong JIN
IPC: C07K16/24 , A61P35/00 , G01N33/50 , G01N33/574
CPC classification number: C07K16/24 , A61P35/00 , G01N33/5058 , G01N33/57407 , A61K2039/505
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
-
Patent Agency Ranking
公开(公告)号：US20220372122A1
公开(公告)日：2022-11-24
申请号：US17723149
申请日：2022-04-18
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Jae Young SEONG , Jong Ik HWANG , Eun Bee CHO , Junho CHUNG , Junyeong JIN , Tae Young YUNE , Jee Youn LEE
IPC: C07K16/18 , G01N33/563 , C07K7/00
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US20220144932A1
公开(公告)日：2022-05-12
申请号：US17290154
申请日：2019-12-31
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Wonkyum KIM , Dong Sik KIM , Jae-Keun LEE , Jeongwon YOON , Junho CHUNG , Junyeong JIN
IPC: C07K16/24
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g, inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US11248023B2
公开(公告)日：2022-02-15
申请号：US16511976
申请日：2019-07-15
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young Seong , Jong-Ik Hwang , Dong-Hoon Kim , Gi Hoon Son , Yoo-Na Lee , Seongsik Yun , Arfaxad Reyes-Alcaraz
IPC: C07K7/08 , A61K38/00 , A61P25/28 , A61P25/30 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/06 , A61K9/00 , A61K9/19
Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
公开(公告)号：US20210347872A1
公开(公告)日：2021-11-11
申请号：US17285861
申请日：2019-10-15
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Dong Sik KIM , Soon-gu KWON
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and/or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.
-
40.发明申请公开(公告)号：US20210070849A1
公开(公告)日：2021-03-11
申请号：US17050056
申请日：2019-04-24
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol KIM , Dong Sik KIM , Soon-gu KWON
Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.02 seconds)
